Catalyst Pharmaceuticals Stock Analysis

CPRX Stock  USD 25.15  0.57  2.22%   
Catalyst Pharmaceuticals is undervalued with Real Value of 30.56 and Target Price of 33.0. The main objective of Catalyst Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Catalyst Pharmaceuticals is worth, separate from its market price. There are two main types of Catalyst Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Catalyst Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Catalyst Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Catalyst Stock trading window is adjusted to America/New York timezone.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

Catalyst Stock Analysis Notes

About 83.0% of the company shares are held by institutions such as insurance companies. The book value of Catalyst Pharmaceuticals was currently reported as 6.02. The company had not issued any dividends in recent years. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people. For more info on Catalyst Pharmaceuticals please contact Richard MBA at 305 420 3200 or go to https://catalystpharma.com.

Catalyst Pharmaceuticals Investment Alerts

Catalyst Pharmaceuticals had very high historical volatility over the last 90 days
Over 83.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: With 81 percent ownership in Catalyst Pharmaceuticals, Inc. , institutional investors have a lot riding on the business

Catalyst Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Catalyst Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
20th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Catalyst Largest EPS Surprises

Earnings surprises can significantly impact Catalyst Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-09
2021-06-300.10.110.0110 
2020-11-09
2020-09-300.10.110.0110 
2020-05-11
2020-03-310.090.10.0111 
View All Earnings Estimates

Catalyst Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Catalyst Pharmaceuticals' ESG score is a quantitative measure that evaluates Catalyst Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Catalyst Pharmaceuticals' operations that may have significant financial implications and affect Catalyst Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.

Catalyst Pharmaceuticals Thematic Classifications

In addition to having Catalyst Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Health Management Idea
Health Management
Healthcare providers, hospitals
Biotech Idea
Biotech
Biotechnology and pharmaceuticals production and services

Catalyst Stock Institutional Investors

Shares
Royce & Associates, Lp2024-12-31
1.9 M
Bank Of America Corp2024-12-31
1.6 M
Northern Trust Corp2024-12-31
1.5 M
Nuveen Asset Management, Llc2024-12-31
1.3 M
Boston Partners Global Investors, Inc2024-12-31
1.3 M
Charles Schwab Investment Management Inc2024-12-31
1.2 M
T. Rowe Price Associates, Inc.2024-12-31
1.2 M
Kennedy Capital Management Inc2024-12-31
M
Jacobs Levy Equity Management, Inc.2024-12-31
913 K
Blackrock Inc2024-12-31
19.4 M
Vanguard Group Inc2024-12-31
8.4 M
Note, although Catalyst Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Catalyst Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.13 B.

Catalyst Profitablity

The company has Profit Margin (PM) of 0.33 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.44 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.44.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.24  0.25 
Return On Capital Employed 0.27  0.28 
Return On Assets 0.19  0.20 
Return On Equity 0.23  0.24 

Management Efficiency

Catalyst Pharmaceuticals has return on total asset (ROA) of 0.1846 % which means that it generated a profit of $0.1846 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2938 %, meaning that it created $0.2938 on every $100 dollars invested by stockholders. Catalyst Pharmaceuticals' management efficiency ratios could be used to measure how well Catalyst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.25 in 2025. Return On Capital Employed is likely to rise to 0.28 in 2025. At this time, Catalyst Pharmaceuticals' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 654.8 M in 2025, whereas Other Assets are likely to drop 1.09 in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 6.14  6.45 
Tangible Book Value Per Share 4.82  5.06 
Enterprise Value Over EBITDA 10.03  10.53 
Price Book Value Ratio 3.40  3.23 
Enterprise Value Multiple 10.03  10.53 
Price Fair Value 3.40  3.23 
Enterprise ValueB2.1 B
The strategic initiatives led by Catalyst Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Operating Margin
0.4431
Profit Margin
0.3333
Beta
0.836
Return On Assets
0.1846
Return On Equity
0.2938

Technical Drivers

As of the 26th of March, Catalyst Pharmaceuticals shows the Mean Deviation of 2.14, risk adjusted performance of 0.0813, and Downside Deviation of 2.3. Catalyst Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Catalyst Pharmaceuticals Price Movement Analysis

Execute Study
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Catalyst Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Catalyst Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Catalyst Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Catalyst Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Catalyst Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Catalyst Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Miller Steve few days ago
Disposition of 11872 shares by Miller Steve of Catalyst Pharmaceuticals subject to Rule 16b-3
 
Del Carmen Jeffrey over three weeks ago
Disposition of 30423 shares by Del Carmen Jeffrey of Catalyst Pharmaceuticals at 22.89 subject to Rule 16b-3
 
Daly Richard J over three weeks ago
Disposition of 4000 shares by Daly Richard J of Catalyst Pharmaceuticals subject to Rule 16b-3
 
Daly Richard J over a month ago
Disposition of 1574 shares by Daly Richard J of Catalyst Pharmaceuticals subject to Rule 16b-3
 
Elsbernd Brian over a month ago
Disposition of 2353 shares by Elsbernd Brian of Catalyst Pharmaceuticals subject to Rule 16b-3
 
Russo Gregg over a month ago
Insider Trading
 
Daly Richard J over two months ago
Disposition of 10600 shares by Daly Richard J of Catalyst Pharmaceuticals subject to Rule 16b-3
 
Del Carmen Jeffrey over two months ago
Disposition of 8667 shares by Del Carmen Jeffrey of Catalyst Pharmaceuticals subject to Rule 16b-3
 
Harper Molly over two months ago
Acquisition by Harper Molly of 1333 shares of Catalyst Pharmaceuticals subject to Rule 16b-3
 
Miller Steve over three months ago
Acquisition by Miller Steve of 235000 shares of Catalyst Pharmaceuticals at 4.01 subject to Rule 16b-3
 
Elsbernd Brian over three months ago
Disposition of 9300 shares by Elsbernd Brian of Catalyst Pharmaceuticals at 21.65 subject to Rule 16b-3
 
Thompson Tamar over three months ago
Acquisition by Thompson Tamar of 23248 shares of Catalyst Pharmaceuticals at 21.12 subject to Rule 16b-3

Catalyst Pharmaceuticals Outstanding Bonds

Catalyst Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Catalyst Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Catalyst bonds can be classified according to their maturity, which is the date when Catalyst Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Catalyst Pharmaceuticals Predictive Daily Indicators

Catalyst Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Catalyst Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Catalyst Pharmaceuticals Corporate Filings

F4
7th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
5th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
28th of February 2025
Other Reports
ViewVerify
10K
26th of February 2025
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
ViewVerify
F4
19th of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13th of February 2025
Other Reports
ViewVerify
8K
24th of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
21st of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Catalyst Pharmaceuticals Forecast Models

Catalyst Pharmaceuticals' time-series forecasting models are one of many Catalyst Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Catalyst Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Catalyst Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Catalyst Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Catalyst shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Catalyst Pharmaceuticals. By using and applying Catalyst Stock analysis, traders can create a robust methodology for identifying Catalyst entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin 0.44  0.46 
Operating Profit Margin 0.40  0.42 
Net Profit Margin 0.33  0.35 
Gross Profit Margin 0.86  0.90 

Current Catalyst Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Catalyst analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Catalyst analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
33.0Strong Buy8Odds
Catalyst Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Catalyst analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Catalyst stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Catalyst Pharmaceuticals, talking to its executives and customers, or listening to Catalyst conference calls.
Catalyst Analyst Advice Details

Catalyst Stock Analysis Indicators

Catalyst Pharmaceuticals stock analysis indicators help investors evaluate how Catalyst Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Catalyst Pharmaceuticals shares will generate the highest return on investment. By understating and applying Catalyst Pharmaceuticals stock analysis, traders can identify Catalyst Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow298.4 M
Common Stock Shares Outstanding124.9 M
Total Stockholder Equity727.6 M
Tax Provision52.4 M
Quarterly Earnings Growth Y O Y0.414
Property Plant And Equipment Net3.6 M
Cash And Short Term Investments517.6 M
Cash517.6 M
Accounts Payable16.6 M
Net Debt-514.8 M
50 Day M A22.499
Total Current Liabilities120.7 M
Other Operating Expenses296.6 M
Non Current Assets Total227.8 M
Forward Price Earnings14.7059
Stock Based Compensation22.3 M

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.